New drug cocktail aims to keep multiple myeloma at bay longer after transplant
NCT ID NCT02659293
First seen Mar 08, 2026 · Last updated May 08, 2026 · Updated 6 times
Summary
This study tests whether adding two extra drugs (carfilzomib and dexamethasone) to standard lenalidomide maintenance therapy after a stem-cell transplant can delay the return of multiple myeloma. About 180 adults who have already had a transplant and are in stable condition will be randomly assigned to receive either the three-drug combo or lenalidomide alone. The main goal is to see if the combo extends the time before the disease worsens.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Polish Myeloma Consortium
Poznan, Poland
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Wayne State University - Karmanos Cacner Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.